A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety, efficacy, pharmacokinetics, and
immunogenicity of MRG004A in patients with Tissue Factor positive advanced or metastatic
solid tumors.